Tiny LNA-based compounds inhibit entire disease-associated microRNA families
Sunday, March 20, 2011 - 14:30
in Biology & Nature
A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.